Peptide library / Immune & defense / Oritavancin
Oritavancin
A long-acting lipoglycopeptide antibiotic given as a single infusion.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Acute bacterial skin infectionsFDA approved
How it is thought to work
Oritavancin blocks cell wall building and damages the membrane of Gram-positive bacteria.
What the evidence shows
Trials showed one dose was as effective as a week or more of vancomycin.
Safety and unknowns
Nausea, headache and infusion reactions. It can interfere with some clotting tests.
Regulatory status
FDA-approved as Orbactiv in 2014 and Kimyrsa in 2021.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
Pexiganan
In clinical trialsA magainin-like peptide cream tested for infected diabetic foot ulcers.
Polymyxin B
FDA-approvedA last-resort cyclic peptide antibiotic, close relative of colistin.
Nangibotide
In clinical trialsA TREM-1 inhibitor peptide tested in septic shock.
General information, not medical advice. Do not buy or inject unregulated peptides.